Biofourmis

AI-Powered Predictive Virtual Care

Singapore, Massachusetts, Singapore

Precision Medicine/Diagnostics Cancer Cardiovascular Disease Infectious Disease Payer InnovationsSeries D+

Biofourmis is a Singapore-based digital therapeutics company that uses continuous monitoring of connected medical devices to manage chronic conditions. It focuses on heart conditions and has demonstrated significant improvements in patient outcomes and cost reduction.

Biofourmis hero image

✓Source: HealthTech Alpha by Galen Growth

Shareable draft

Check out Biofourmis on @MedStartr Today Biofourmis is a Singapore-based digital therapeutics company that uses continuous monitoring of connected medical devices to manage chronic conditions. It focuses on heart conditions and has demonstrated significant improvements in patient outcomes and cost reduction. #ChronicHeartConditions #HeartFailure #Hypertension #Diabetes #LipidManagement #AtrialFibrillation #AcuteCoronarySyndrome #Gout #ChronicKidneyDisease #MentalBehavioralHealth #Asthma #COPD #ChronicPain #InfectiousDiseases #CancerOncology #PrecisionMedicineDiagnostics #Cancer #CardiovascularDisease #InfectiousDisease #PayerInnovations #MedMo #MedStartrVentures

https://www.medstartr.ai/s/Wp4fkVQ-gcw

Get Involved in Biofourmis

How We Help

Problem Statement

Healthcare organizations face challenges with suboptimal patient outcomes, high hospital readmission rates, inefficient chronic disease management, and escalating costs. Biofourmis addresses these by enabling personalized, predictive in-home care and accelerating drug development.

Core Technology

digital therapeutics through continuous monitoring of connected medical devices

Key Differentiators

Detects heart failure decompensation 21 hours earlier than standard care

Clinical Focus

ambulatory physiologic monitoring

Target Customers

["Hospitals", "Health systems", "Payers", "Biopharmaceutical companies"]

Product Stage

Mature

Company Info

Business Model: B2B, SaaS
Founded: 2016
Total Funding: Only accessible to MedStartr community members. Join now
Only accessible to MedStartr community members.
Join now
Website: biofourmis.com/

Disease Areas

Chronic Heart Conditions Heart Failure Hypertension Diabetes Lipid Management Atrial Fibrillation Acute Coronary Syndrome Gout Chronic Kidney Disease Mental Health Asthma COPD Chronic Pain Infectious Diseases Cancer & Oncology

Technologies

Machine LearningHealth AnalyticsWearable SensorsDigital TherapeuticsVirtual CareCloud PlatformsAI & Machine Learning

🌐Website

MedStartr Engagement Score

The MedStartr Index is a reflection of how the crowds that come to MedStartr everyday to find healthcare innovations reacted. Calculated by our AI agent Fyggy based on algorithms we have been building since 2012 and over 100 different factors, the math is proprietary and complex. Suffice to say, it has been found to be highly correlative with early stage company growth. What you see here is the public version. To learn more or to get deeper access to our predictive data on startup success for your fund or company, click here.

Comments

Comments from new members are shown once the company's team has approved them. Please follow the community rules.

Be the first to comment.

What do you think of Biofourmis?

A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.

Clinical Benefit Potential

The potential for a project to have a large and significant impact on medical care, treatment, or prevention.

Feasibility

The likelihood that this will provide benefit for patients / care givers and that the founders can execute on their vision and plan.

Innovativeness

The distinguishing features, concept, or technology that differentiates the entry compared to others that already exist and are in widespread use.

Fundability

The reviewers' beliefs that the idea is fundable or can make it to sustainability without outside investment.

Scalability

Some great ideas are destined to failure because they are too complex or too expensive. The reviewer should consider the likelihood that a project as explained, or perhaps with some tweaks, could possibly become a worldwide solution within a reasonable time frame.

Presentation Quality

How well the team presented the idea.

Submit anonymously — my name won't be shown to the team or on this profile

Your scores and comments are shown with your review on this company's profile.